VIVOLTA
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Early VC | ||
* | €1.5m | Seed | |
* | N/A | €1.5m | Debt |
* | €7.0m | Early VC | |
* | N/A | Grant | |
Total Funding | $9.4m |
Related Content
Recent News about VIVOLTA
EditVivolta specializes in nanofiber-based technology to revolutionize drug delivery and medical device development. Operating in the healthcare sector, Vivolta serves pharmaceutical companies, medical device manufacturers, and healthcare providers. The company focuses on creating solutions for localized drug delivery, minimizing adverse effects of systemic treatments, and enhancing the efficacy of existing active pharmaceutical ingredients (APIs). Additionally, Vivolta's technology is pivotal in tissue engineering, offering applications in soft tissue repair, cardiovascular and dental implants, nerve repair devices, advanced wound dressings, and ophthalmology solutions. The business model revolves around partnering with clients to develop customized, resorbable nanofiber implants and devices, generating revenue through research and development contracts, licensing agreements, and product sales.
Keywords: nanofiber technology, localized drug delivery, tissue engineering, medical devices, healthcare innovation, pharmaceutical solutions, soft tissue repair, cardiovascular implants, nerve repair, advanced wound dressings.